OncoMatch/Clinical Trials/NCT06566586
A Clinical Study to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for the Treatment of B-cell Lymphoma
Is NCT06566586 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies TQB3702 tablets+Chemotherapy regimen for b-cell lymphoma.
Treatment: TQB3702 tablets+Chemotherapy regimen — To evaluate the efficacy and safety of TQB3702 tablets combined with immunochemotherapy for the treatment of B-cell lymphoma
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: systemic standard therapy — relapsed/refractory indolent B-cell lymphoma
Relapsed/refractory inert B-cell lymphoma: have received at least one previous line of systemic standard therapy
Cannot have received: allogeneic hematopoietic stem cell transplantation
previous allogeneic hematopoietic stem cell transplantation
Cannot have received: autologous hematopoietic stem cell transplantation
Exception: within 3 months before the first treatment
autologous hematopoietic stem cell transplantation within 3 months before the first treatment
Lab requirements
Blood counts
The main organs function well.
Kidney function
The main organs function well.
Liver function
The main organs function well.
Cardiac function
The main organs function well.
The main organs function well.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify